Stem cell therapy for diabetes management. Research on MSC treatments for Type 1 and Type 2 diabetes, insulin production improvement, and long-term blood sugar control strategies.
Type 2 diabetes involves insulin resistance and progressive beta-cell dysfunction. MSC therapy addresses both mechanisms: improving insulin sensitivity through anti-inflammatory paracrine signaling and supporting residual beta-cell regeneration. For Type 1 diabetes, MSCs modulate the autoimmune attack on beta cells.
Multiple clinical trials report significant reductions in HbA1c, fasting glucose, and insulin requirements after MSC therapy. Some patients achieve complete medication independence. Additional metabolic benefits include improved kidney function, reduced peripheral neuropathy, and better cardiovascular risk profiles.
Diabetic patients receive 2-3 sessions of IV MSC infusion (100-200 million cells per session). Pre-treatment includes comprehensive metabolic profiling (HbA1c, fasting insulin, C-peptide) and post-treatment follow-up tracks metabolic markers at 1, 3, 6, and 12 months with medication adjustments guided by your endocrinologist.
Related articles: Cardiovascular Regeneration with Stem Cells (2026 Research) | Understanding Stem Cell Therapy (2026 Complete Guide) | Anti-Aging Cellular Rejuvenation (2026 Guide)
Related treatments: Diabetes Stem Cell Therapy | Kidney Disease Stem Cell Therapy | Hepatitis Stem Cell Therapy
Pillar: stem cell therapy for liver disease in Istanbul
Related treatments: hepatitis stem cell treatment in Istanbul | diabetes stem cell therapy in Turkey | kidney disease MSC treatment in Istanbul | COPD stem cell therapy in Turkey
Research & guides: MSC therapy for diabetes management in Turkey | stem cell treatment for liver cirrhosis and fibrosis in Istanbul